Maggie Cu Cheang

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi Gene expression profiling of breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia V6H 3Z6, Canada
    Annu Rev Pathol 3:67-97. 2008
  2. ncbi Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
    Jill E Kucab
    British Columbia Research Institute for Children s and Women s Health, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
    Breast Cancer Res 7:R796-807. 2005
  3. ncbi Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007

Collaborators

  • Torsten O Nielsen
  • Matt van de Rijn
  • Marc Tischkowitz
  • Jill E Kucab
  • Louis R Begin
  • Lars A Akslen
  • David G Huntsman
  • William D Foulkes
  • Jean Sebastien Brunet
  • Sandra E Dunn
  • Michael Pollak
  • Cathy Lee
  • Ching-Shih Chen
  • C Blake Gilks
  • David Huntsman
  • Erika Yorida
  • Jiuxiang Zhu
  • Joanne Emerman
  • Ching Shih Chen

Detail Information

Publications3

  1. ncbi Gene expression profiling of breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia V6H 3Z6, Canada
    Annu Rev Pathol 3:67-97. 2008
    ..Prospective trials are now underway to determine the value of such tools for clinical decision making in breast cancer; these efforts may serve as a model for using such approaches in other tumor types...
  2. ncbi Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
    Jill E Kucab
    British Columbia Research Institute for Children s and Women s Health, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
    Breast Cancer Res 7:R796-807. 2005
    ..We therefore examined the potential of these compounds in the treatment of breast cancer. The analogues were characterized in MDA-MB-453 cells because they overexpress HER-2 and have very high levels of P-Akt...
  3. ncbi Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...